Drug Topics
FEBRUARY 20, 2025
Tirzepatide (Mounjaro, Zepbound), a glucagon-like peptide-1 (GLP-1) medication, demonstrates improved diabetes control and decreases in insulin requirements.
STAT
FEBRUARY 20, 2025
In ongoing trials of Eli Lilly’s next-generation obesity drug, several trial participants are running into an issue they never expected: They are losing too much weight. One participant lost 22% of her weight in nine months — substantially faster than the rate seen with approved GLP-1 drugs like Wegovy or Zepbound. Her weight dropped so much that researchers reduced her dose of the treatment, called retatrutide.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
FEBRUARY 20, 2025
From market pressures to regulatory framework, Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed growth in the business of health-system pharmacy and the challenges it has faced.
STAT
FEBRUARY 20, 2025
Mainstream policy analysts are convinced that government, and only government, can save us from the monster the U.S. health care system has become. That’s why their recommended solutions to the system’s many problems all have government at their core.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Topics
FEBRUARY 20, 2025
Researchers conducted a literature review to explore topics in entrepreneurship that impact pharmacy practice and education.
Pharmacy Times
FEBRUARY 20, 2025
Panelists discuss how pharmacists play a crucial role in optimizing health outcomes for women with complex health needs through comprehensive medication management, personalized consultations, and interdisciplinary collaboration. They provide targeted medication therapy, monitor drug interactions, offer medication counseling, manage chronic conditions, support reproductive health, and help patients navigate complex treatment regimens with expertise and compassionate care.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
FEBRUARY 20, 2025
Change has come to the Department of Health and Human Services. With the confirmation of Robert F. Kennedy Jr. as secretary, major shifts in organizational structure, staffing , and policy priorities across the department are already underway. But not all HHS agencies are created equal, and some deserve to be modified with a scalpel rather than a sledgehammer.
Drug Topics
FEBRUARY 20, 2025
Experts gathered to explore the pathophysiology and therapeutic management of burn injury-induced pain.
STAT
FEBRUARY 20, 2025
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I was a bit worried last week’s angst-y rant on the bleak state of biotech investing would turn folks off. In fact, it was my most popular newsletter ever, with the version posted to STAT’s website delivering a ton of new subscribers.
Drug Topics
FEBRUARY 20, 2025
Recently, the FDA alerted users of missed notifications for continuous glucose monitoring devices and Bluetooth smartphone compatibility.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
FEBRUARY 20, 2025
PfSPZ-LARC2 is a genetically engineered malaria vaccine that marks a significant step forward in combating malaria around the world.
Drug Topics
FEBRUARY 20, 2025
A program that includes peer coaching and monitoring tools can help pharmacists better manage hypertension in patients.
Pharmacy Times
FEBRUARY 20, 2025
Panelists discuss how menopause represents a complex physiological transition characterized by hormonal fluctuations, reproductive system changes, and multifaceted symptoms affecting physical, psychological, and metabolic health. Comprehensive patient education, personalized management strategies, and holistic support are crucial for navigating this transformative life stage.
Drug Topics
FEBRUARY 20, 2025
By 12 weeks, investigators report that SkinTE facilitated significantly more wound closures compared with the standard of care.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
FEBRUARY 20, 2025
Semaglutide has been approved for reducing kidney disease progression and cardiovascular risk in patients with type 2 diabetes, marking a significant advancement in CKD management.
STAT
FEBRUARY 20, 2025
Every time you get sick, your body keeps a record of it.
Pharmacy Times
FEBRUARY 20, 2025
There was an association observed between fluctuating low-density lipoprotein cholesterol and the risk of developing dementia and cognitive impairment.
PharmaVoice
FEBRUARY 20, 2025
Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
PhRMA
FEBRUARY 20, 2025
The innovation that happens every day in America’s biopharmaceutical companies prevents disease, transforms lives and creates a healthier America. While we know there are still serious illnesses that remain to be conquered, the progress we’ve made in the past 25 years has changed the lives of countless patients and their families.
STAT
FEBRUARY 20, 2025
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! Got a meaty newsletter for you today, so let’s dive in.
Pharmaceutical Technology
FEBRUARY 20, 2025
The FDA, NIH and CDC has cut 5,200 probationary staff in a job cull across the HHS over the Valentine's Day weekend.
Fierce Healthcare
FEBRUARY 20, 2025
Community Health Systems posted a $70 million loss in the fourth quarter of 2024, according to its earnings report released on Tuesday. | Community Health Systems posted a $70 million loss in the fourth quarter of 2024, according to its earnings report released on Tuesday.
pharmaphorum
FEBRUARY 20, 2025
SMA treatment with Evrysdi 'could start prenatally' Phil.
Fierce Healthcare
FEBRUARY 20, 2025
In a newly inked partnership, virtual primary care provider HealthTap is working with NaphCare to provide virtual, on-demand care to people that have exited the federal prison system. Many of these individuals have untreated chronic conditions and higher social needs than other populations.
STAT
FEBRUARY 20, 2025
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning, let’s get straight into the news today — including one story I’ve been spending some time on.
Pharmacy Times
FEBRUARY 20, 2025
Using central obesity measures provides more accurate estimates of the proportion of CRC cases attributable to excess weight compared to using BMI alone.
STAT
FEBRUARY 20, 2025
How will cuts to Food and Drug Administration staff affect the drug industry? Are companies pushing for too much weight loss from new drugs? And what will bring biotech out of its doldrums? We discuss all that and more on the latest episode of “The Readout LOUD.” Mizuho analyst Jared Holz joins to discuss Adam’s column on biotech’s dark period.
pharmaphorum
FEBRUARY 20, 2025
Boehringer Ingelheim's oral HER2 inhibitor zongertinib has started an FDA review as a lung cancer treatment with a decision due in the third quarter.
Pharmacy Times
FEBRUARY 20, 2025
Treatment with semaglutide yielded superior effects on drinking outcomes compared with existing therapies to reduce alcohol cravings.
Fierce Healthcare
FEBRUARY 20, 2025
Healthcare applications, devices, AI scribes and digital health products can be built on Corti's foundation model that was trained exclusively on healthcare data. The partnership with Wolters Kluwer will allow product developers to integrate UpToDate into new products.
Pharmacy Times
FEBRUARY 20, 2025
Improvements in baseline for markers of hemolysis (indirect bilirubin, lactate dehydrogenase, and haptoglobin) were observed only in the mitapivat arm.
pharmaphorum
FEBRUARY 20, 2025
Around 1,400 patients with Lennox-Gastaut Syndrome will be eligible for NHS treatment with UCB's Fintepla after a NICE recommendation
Pharmacy Times
FEBRUARY 20, 2025
Priority review status will allow for expedited development of zongertinib, putting it on the path toward approval as the first in a new class of drugs for mutated NSCLC.
Expert insights. Personalized for you.
453 
Let's personalize your content